glp-1 and afib Effects of Glucagon-Like Peptide-1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation GLP‑1 Therapy Improves Atrial Fibrillation

222 Although limited direct evidence has evaluated use of GLP-1s with or without RDN-provided MNT, the SCALE, 13 STEP 1, 14 SURMOUNT, 15 and STEP 3 178 trials each demonstrated substantial weight reduction by combining GLP-1s with regular counseling sessions by RDNs or other qualified healthcare professionals (such lifestyle support was also provided to the placebo group in each trial)

Research in earlier phases or small trials include evaluation of GLP-1s for cystic fibrosis-related diabetes, polycystic ovarian syndrome (PCOS), chronic obstructive pulmonary disease (COPD), Prader-Willi syndrome (PWS), asthma, substance or alcohol use disorder and as add-on to insulin for type 1 diabetes

Suppose, instead, that the microbes used for production were also edible

either in leptin deficient or selective expression of leptin receptors in GLP1 neurons)

It is not approved for human or veterinary applications and must not be used for diagnostic or therapeutic purposes